Quantum BioPharma Receives Health Canada Product License for Qlarity Natural Health Product
TL;DR
Quantum BioPharma gains a competitive edge with Health Canada's Qlarity license, expanding market reach and potential revenue from Canadian sales.
Health Canada granted Quantum BioPharma a product license for Qlarity, permitting its sale with specified uses based on regulatory approval processes.
Qlarity's approval supports public health by aiding energy, cognition, and fatigue reduction, contributing to improved daily wellness in Canada.
Quantum BioPharma's Qlarity, now licensed in Canada, offers a natural boost for mental alertness and endurance, building on its U.S. counterpart unbuzzd.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a Product License from Health Canada for its natural health product Qlarity, designated under Product Number 80144141. This authorization permits the sale of Qlarity in Canada, with recommended uses including support for energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction. The approval marks a significant regulatory milestone for the company, enabling market entry into Canada and complementing its existing product portfolio.
The company previously licensed a similar product in the United States under the brand name unbuzzd™, demonstrating its strategic approach to expanding its consumer health offerings across North America. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments of 7% of sales from unbuzzd™ until cumulative payments reach $250 million, after which the royalty decreases to 3% in perpetuity. Additionally, the company maintains full rights to develop similar products or alternative formulations for pharmaceutical and medical applications, preserving flexibility for future innovations.
This development is part of Quantum BioPharma's broader focus on building a portfolio of innovative assets for treating neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of multiple sclerosis. Further details on the company's progress and updates are available in its newsroom at https://ibn.fm/QNTM.
The Health Canada license for Qlarity underscores the growing recognition of natural health products in supporting cognitive and metabolic functions, potentially benefiting consumers seeking non-pharmaceutical options for wellness. For the industry, it highlights the importance of regulatory compliance and cross-border market strategies, while for investors, it reflects Quantum BioPharma's execution capability in navigating complex regulatory environments. The move may also stimulate increased interest in the natural health product sector, aligning with global trends toward preventive health and holistic well-being.
Curated from InvestorBrandNetwork (IBN)
